A device, comprising at least one monochromatic light source configured to generate a first optical trap; an ensemble of particles disposed in the first optical trap, each particle of the ensemble of particles being excitable to a first Rydberg state and a second Rydberg state, the second Rydberg state having a blockade radius, each particle of the ensemble of particles being within the blockade radius of each other and within the blockade radius of an atomic qubit, the atomic qubit being a particle that is excitable to the second Rydberg state, the ensemble of particles having a first transmissivity at a first wavelength when neither any particle of the ensemble of particles nor the atomic qubit is in the second Rydberg state, the ensemble of particles having a second transmissivity at the first wavelength when the atomic qubit is in the second Rydberg state, the second transmissivity being lower than the first transmissivity; and a second monochromatic light source configured to drive each particle of the ensemble of particles into the first Rydberg state; a probe light source configured to direct a probe beam having the first wavelength to the ensemble of particles; and a photosensor configured to determine the state of the atomic qubit.
A dry shape memory adhesive material for adhering a target surface in the presence of fluid and for providing tunable mechanical contraction of an adhered surface. The dry shape memory adhesive material is pre-stretched and dried to provide an adhesive structure that implements a hydration-based shape memory mechanism to achieve both uniaxial and biaxial contractions of the adhered surface. According to preferred embodiments, the shape memory adhesive material includes a combination of one or more hydrophilic polymers or copolymers, one or more amine coupling group, and one or more cross linkers.
A61L 15/22 - Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
A61L 15/42 - Use of materials characterised by their function or physical properties
A shape memory adhesive material for adhering and contracting wounds, particularly diabetic wounds, to facilitate their closure and healing. The shape memory adhesive is pre- stretched and dried to provide an adhesive structure with a pre-programmed strain, wherein the adhesive is capable of rapid robust adhesion followed by predictive contraction upon contact with a wet surface. According to preferred embodiments, the shape memory adhesive material includes a combination of one or more hydrophilic polymers or copolymers, one or more amine coupling group, and one or more cross linkers.
Schemes are described for joint geometry and placement in superconducting magnets. According to some aspects, a joint may be implemented in a modular component of a superconducting magnet, such as a plate that includes a spiral superconducting path, with the joints providing electrically conductive connections between the superconducting paths of adjacent plates. A joint may be installed and coupled to the component (e.g., plate) after its fabrication, thereby providing freedom in design of both the joint and the component. In at least some cases, the joints may be arranged to be flush with a surface of the component after installation into the component so that neighboring instances of the components may be stacked flush with one another, thereby putting joints from the neighboring components into intimate contact with one another.
This disclosure provides a method for substantially increasing the concentration of cfDNA in a patient. By injecting a patient with lipid and/or polymer nanoparticles, agents that bind cfDNA, or inhibit deoxyribonucleases prior to collection of a sample of cfDNA, e.g., by way of a liquid biopsy, major pathways for the degradation of cfDNA are temporarily blocked, permitting transient accumulation of cfDNA. This strategy has the potential to dramatically enhance the quality of detection achieved by downstream cfDNA analytical applications, such as sequencing applications.
C08L 101/12 - Compositions of unspecified macromolecular compounds characterised by physical features, e.g. anisotropy, viscosity or electrical conductivity
G01N 33/551 - Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being inorganic
Systems, methods and composition for targeting polynucleotides are detailed herein. In particular, engineered DNA-targeting systems comprising novel TnpB polypeptides and a reprogrammable targeting nucleic acid component and methods and application of use are provided.
The present application provides systems, methods and compositions used for targeted gene modification, targeted insertion, perturbation of gene transcripts, nucleic acid editing. Novel nucleic acid targeting systems comprise components of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems and transposable elements. Specifically, the disclosure provides an engineered composition comprising: a programmable DNA-binding protein and two or more Tn7-like transposition proteins, wherein at least one of the Tn7-like transposition proteins is connected to the DNA-binding protein or otherwise capable of forming a complex with the DNA-binding protein, wherein the DNA-binding protein comprising a Cas protein including a Cas12k protein, and wherein two or more Tn7-like transposition proteins consisting of TnsB, TnsC, and TniQ.
C07H 21/04 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
Topological qubits are provided in a quantum spin liquid. In various embodiments, a device is provided comprising a two-dimensional array of particles, each particle disposed at a vertex of a ruby lattice having a parameter ? greater than AA; each particle having a first state and an excited state; each particle that belongs to at least three unit cells of the ruby lattice having a blockade radius, when in the excited state, sufficient to blockade each of at least six nearest neighboring particles in the ruby lattice from transitioning from its first state to its excited state, and wherein the array has at least one outer edge configured to be in a first boundary condition.
Provided herein are compositions and methods comprising engineered microorganisms and their use for locally degrading an antibiotic in the gastrointestinal tract to prevent or limit death of beneficial flora.
A thermal energy storage system includes a firebrick checkerwork and an electrode. The firebrick checkerwork includes one or more conductive firebrick layers, each including a plurality of electrically conductive doped metal oxide firebricks with one or more airflow vents. The electrode includes one or more electrode firebrick layers, each layer including a plurality of electrode firebricks. The firebrick checkerwork is heated due to application of electrical power to the electrode. Air flowing through the firebrick checkerwork may then be heated for use in heat-related applications (e.g., an industrial application, commercial application, residential application, transportation application, etc.) some of which may relate to electricity production or in other applications which may relate to other purposes that require heat that are unrelated to electricity production.
This disclosure provides systems, methods, and compositions for site-specific genetic engineering using Programmable Addition via Site-Specific Targeting Elements (PASTE). PASTE comprises the addition of an integration site into a target genome followed by the insertion of one or more genes of interest or one or more nucleic acid sequences of interest at the site. PASTE combines gene editing technologies and integrase technologies to achieve unidirectional incorporation of genes in a genome for the treatment of diseases and diagnosis of disease.
Systems, methods and compositions for targeting polynucleotides are detailed herein. In particular, engineered DNA-targeting systems comprising IscB polypeptides, novel IscB nucleases and reprogrammable targeting nucleic acid components and methods and application of use are provided.
NetCast is an optical neural network architecture that circumvents constraints on deep neural network (DNN) inference at the edge. Many DNNs have weight matrices that are too large to run on edge processors, leading to limitations on DNN inference at the edge or bandwidth bottlenecks between the edge and server that hosts the DNN. With NetCast, a weight server stores the DNN weight matrix in local memory, modulates the weights onto different spectral channels of an optical carrier, and distributes the weights to one or more clients via optical links. Each client stores the activations, or layer inputs, for the DNN and computes the matrix-vector product of those activations with the weights from the weight server in the optical domain. This multiplication can be performed coherently by interfering the spectrally multiplexed weights with spectrally multiplexed activations or incoherently by modulating the weight signal from the weight server with the activations.
H04B 10/80 - Optical aspects relating to the use of optical transmission for specific applications, not provided for in groups , e.g. optical power feeding or optical transmission through water
14.
BIOADHESIVE MATERIALS AND MINIMALLY INVASIVE METHODS FOR ADHERING TISSUES WITH BIOADHESIVE MATERIALS
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (MAYO) (USA)
Inventor
Zhao, Xuanhe
Yuk, Hyunwoo
Wu, Sarah J.
Nabzdyk, Christoph
Abstract
Bioadhesive materials and methods for adhering biological tissues and blood vessels in a minimally invasive manner, wherein the bioadhesive materials are in folded bioadhesive sleeve configurations or in injectable bioadhesive forms adapted for delivery using minimally invasive procedures. The folded bioadhesive sleeve is disposed on the distal portions of a variety of minimally invasive devices for insertion to a target tissue site, then deployed and adhered to the target tissue site through actuation of the minimally invasive device. The injectable bioadhesive is disposed in a syringe and delivered to a target site via a catheter, then adhered to the target tissue by actuation of a minimally invasive device. Precise placement and adhesion to the target tissue site can be successfully accomplished solely through the actuation of the minimally invasive devices without the use of additional devices to assist in placement or actuation of the bioadhesive materials.
Systems and methods for targeted gene modification, targeted insertion, perturbation of gene transcripts, and nucleic acid editing. The novel nucleic acid targeting systems can comprise components of one or more transposases, one or more components of a CRISPR-Cas system, and a transposable element.
This disclosure provides systems, methods, and compositions for RNA-guided RNA- targeting CRISPR effectors for the treatment of diseases as well as diagnostics. In some embodiments, nucleotide deaminase functionalized CRISPR systems for RNA editing RNA knockdown, viral resistance, splicing modulation, RNA tracking, translation modulation, and epi-transcriptomic modifications are disclosed.
Aspects of the disclosure relate to non-naturally occurring polynucleotides encoding a Shank3 protein, AAV vectors comprising the polynucleotides, and gene therapy methods.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
A drug delivery device for administration to a subject may include a reservoir containing an active pharmaceutical ingredient and a potential energy source. The drug delivery device may also include a trigger operatively associated with the potential energy source. The trigger may be configured to actuate at a predetermined location within the subject to deploy a jet of the active pharmaceutical ingredient into a tissue of an adjacent portion of the gastrointestinal tract. In some instances, the jet may be deployed into tissue of the stomach and/or small intestine of the subject. Further, in some embodiments, the operating parameters of the jet may be selected such that the jet penetrates the tissue of the gastrointestinal tract to form a depot of the active pharmaceutical ingredient disposed within the tissue.
Compositions including solid forms of polypeptides such as crystalline antibodies, and related methods, are generally described. The compositions may include carriers such as hydrogels that at least partially encapsulate the solid form of the polypeptides (e.g., crystals, amorphous solids). Encapsulation with certain of the materials described may result in compositions containing relatively high loadings of polypeptides while in some instances retaining structural and functional properties of the polypeptides useful for certain types of administration to subjects (e.g., for prophylactic or therapeutic applications). In some instances, compositions having relatively low dynamic viscosities while having relatively high polypeptide loadings are provided.
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
Described herein are muscle-specific targeting moieties and compositions including the muscle specific targeting motifs. Also described herein are uses of the muscle-specific targeting motifs and compositions including the muscle specific targeting moieties. In some embodiments, the muscle-specific targeting moieties and compositions including the muscle specific targeting moieties can be used to direct delivery of a cargo to a muscle cell.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
Disclosed herein are systems and methods for processing ash. For example, in certain embodiments, the method comprises dissolving at least a portion of ash in acid. In some embodiments, the acid is produced in a reactor. In some embodiments, dissolving at least a portion of ash in acid produces refined silica (SiO2) (e.g., amorphous silica, substantially pure silica, and/or a substantial amount of silica). According to certain embodiments, the ash can be further processed (e.g., using electro winning, pH- based precipitation, and/or electrorefining) to obtain other components instead of or in addition to refined silica.
The present application provides systems, methods and compositions used for targeted gene modification, targeted insertion, perturbation of gene transcripts, nucleic acid editing. Novel nucleic acid targeting systems comprise components of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems and transposable elements.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
THE GENERAL HOSPITAL CORPORATION - DBA MASS GENERAL HOSPITAL (USA)
Inventor
Al'Khafaji, Aziz
Blainey, Paul
Babadi, Mehrtash
Garimella, Kiran V
Hacohen, Nir
Smith, Jonathan Theodore
Abstract
The present disclosure relates to compositions and methods for nucleic acid sequencing, and specifically, at least in certain aspects, provides methods and compositions for enhancing the efficacy, throughput and/or yield of known long-range sequencing platforms, by providing chimeric arrays of input sequences. Such arrays of component nucleic acid sequence elements can be prepared via methods that minimize introduction of bias. The application of the current methods to obtain isoform sequencing information, e.g., from patient samples is specifically also provided, as are methods for mitochondrial lineage tracing that employ the instant chimeric amplicon sequencing processes. Methods and systems for array nucleic acid sequence processing and interpretation are also provided.
UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS (USA)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
THE GENERAL HOSPITAL CORPORATION D.B.A MASSACHUSETTS GENERAL HOSPITAL (USA)
Inventor
Rasalingam, Ravi
Ward, Tarsha
Roche, Ellen T.
Venegas, Jose
Abstract
An oral appliance and method for treating a sleep disorder in a subject are disclosed. The appliance includes, among other elements, a palatal overlay element that engages a portion of the dorsal surface of the subject's tongue, stabilizing the tongue in a superior direction toward the hard palate. The method generally involves stabilizing the dorsal surface of a subject's tongue in a superior direction toward the subject's hard palate.
An adhesive material that provides fast and robust adhesion on wet surfaces, where the adhesion formed is detachable on-demand. The adhesive material is formed of one or more hydrophilic polymers or copolymers grafted with one or more amine coupling groups via a plurality of cleavable physical bonds and/or cleavable covalent bonds and one or more cross linkers. Application of the adhesive material on a wet surface causes the adhesive material to absorb liquid to thereby swell the adhesive material to form a layer of hydrogel, resulting in the formation of temporary crosslinks followed by covalent crosslinks with the surface. Introducing a triggering agent cleaves the cleavable physical bonds and/or cleavable covalent bonds to allow for non-traumatic detachment of the adhesive material from the surface.
Magnets and magnet systems include stacked magnet baseplates. Each of the plates includes grooves that contain windings of a conductor (e.g. a high temperature superconductor) that generates a magnetic field when current is passed through. This field generates Lorentz forces in the stack that press the conductors in different directions and with different magnitudes. Thus, the plates are oppositely oriented (mirrored) so that these forces always press the conductors into the grooves, rather than pulling them out of the grooves. The conductors may be further reinforced in their grooves with solder or epoxy potting. Some stacks may have more plates in one orientation than in the mirrored orientation, because the Lorentz forces need not be symmetrical with respect to a midpoint of the stack, e.g. when the system experiences externally-applied magnetic fields. Additional, mirrored side plates may be added in some configurations.
Techniques are described for lowering strains applied to superconducting material in a superconducting magnet by arranging structural partitions between turns of the superconducting material that intercept and transfer strain to a mechanically stronger structure, such as the housing of the magnet. A structural partition may be formed with a feedthrough slit so that the superconducting material can easily pass through the partition. A number of structural partitions may be interspersed between groups of turns of superconducting material in a magnet so that forces can be sufficiently distributed by the partitions throughout the magnet. At the same time, the number of structural partitions may be selected to minimize the amount of space within the magnet occupied by the partitions that could otherwise be occupied by current-carrying superconducting material.
H01F 6/06 - Coils, e.g. winding, insulating, terminating or casing arrangements therefor
H01F 41/04 - Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformers; Apparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for manufacturing cores, coils or magnets for manufacturing coils
H01F 6/02 - Quenching; Protection arrangements during quenching
28.
COMPOSITIONS OF POLYMERIC MICRODEVICES AND THEIR USE IN CANCER IMMUNOTHERAPY
Microparticulate compositions and methods for delivery and pulsatile release of one or more sting agonists and/or receptors have been developed. The compositions include polymeric microdevices formed from biodegradable and biocompatible polymers or co-polymers thereof including a shell and compartment(s) or discrete regions in the compartment(s) formed by an additive process such as micromolding, three-dimensional printing and lithography. The compositions include microdevices that release individual doses of incorporated STING agonist and/or receptors at defined times, for example, in pulses up to several months after administration with essentially no leakage between releases.
Described in several exemplary embodiments are compositions including a targeting moiety effective to target a central nervous system cell and formulations thereof. In certain embodiments, the targeting moiety is composed of a n-mer motif, P motif, or both. Also described in certain example embodiments are vector systems configured to generate polypeptides containing the one or more targeting moieties. Also described herein are methods of generating a targeting moiety effective to target a central nervous system cell and using the compositions containing the targeting moieties described herein, such as to deliver a cargo to a subject and/or treat a central nervous system disease, disorder, or system thereof.
Disclosed herein are methods of using reactor outputs to purify materials. For example, methods of using acid and/or base produced in a reactor to purify materials (e.g., limestone, dolomite, waste streams, and/or ash) are described herein. Related systems are also described.
ADVANCED FUNCTIONAL FABRICS OF AMERICA, INC. (USA)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
Inventor
Chung, Chia-Chun
Cox, Jason
Deisenhaus, Joshua
Mccarthy, Kristina
Mulherin, Kristen
Nguyen, Jimmy
Rein, Michael
Bernasconi, Matthew
Cantley, Lauren
Parameswaran, Lalitha
Rickley, Michael
Stolyarov, Alexander
Abstract
Methods of manufacturing multi-material fibers having one or more electrically-connectable devices disposed therein are described. In certain instances, the methods include the steps of: positioning the electrically-connectable device(s) within a corresponding pocket provided in a preform material; positioning a first electrical conductor longitudinally within a first conduit provided in the preform material; and drawing the multi-material fiber by causing the preform material to flow, such that the first electrical conductor extends within the multi-material fiber along a longitudinal axis thereof and makes an electrical contact with a first electrode located on each electrically-connectable device. A metallurgical bond may be formed between the first electrical conductor and the first electrode while drawing the multi-material fiber and/or, after drawing the multi-material fiber, the first electrical conductor may be located substantially along a neutral axis of the multi-material fiber.
B29C 70/88 - Shaping composites, i.e. plastics material comprising reinforcements, fillers or preformed parts, e.g. inserts characterised primarily by possessing specific properties, e.g. electrically conductive or locally reinforced
D01D 5/00 - Formation of filaments, threads, or the like
H01B 1/14 - Conductive material dispersed in non-conductive inorganic material
H01B 1/20 - Conductive material dispersed in non-conductive organic material
H01B 13/14 - Insulating conductors or cables by extrusion
32.
CONDUCTOR AND COOLANT SCHEMES FOR SPIRAL-GROOVED, STACKED PLATE, NON-INSULATED SUPERCONDUCTING MAGNETS
Schemes are described for conductor and coolant placement in stacked-plate superconducting magnets, including arranging coolant channels and conducting channels within the plates on opposing faces. If the two types of channels are aligned with one another across the plate stacks, the plates may be stacked such that the cooling channel in one plate is adjacent to the conducting channel of the neighboring plate. By stacking a number of these plates, therefore, cooling may be supplied to each conducting channel through the cooling channels of each neighboring plate. Moreover, by aligning the two types of channels, the stacks of plates may have improved mechanical strength because mechanical load paths through the entire stack that do not pass through any of the channels may be created. This arrangement of channels may produce a very strong stack of plates that can withstand high Lorentz loads.
H01F 6/06 - Coils, e.g. winding, insulating, terminating or casing arrangements therefor
H01F 41/04 - Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformers; Apparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for manufacturing cores, coils or magnets for manufacturing coils
33.
PASSIVE QUENCH PROTECTION TECHNIQUES FOR NON-INSULATED SUPERCONDUCTING MAGNETS
According to some aspects, techniques are described for designing non-insulated (NI) high temperature superconductor (HTS) magnets that mitigate problems that may arise during quench initiation and propagation. Coupling the HTS material to a co-conductor along its length reduces the effective resistance of the conductive path along the HTS material when it is not superconducting, and that this leads to numerous advantages for quench mitigation.
MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (USA)
Inventor
Zhao, Xuanhe
Yuk, Hyunwoo
Mao, Xinyu
Nabzdyk, Christoph
Abstract
A tissue adhesive material that provides fast and robust adhesion even on tissue surfaces covered in bodily fluids. The tissue adhesive material is formed of a hydrophobic matrix and a plurality of bioadhesive microparticles dispersed within the hydrophobic matrix configured such that disposing the adhesive material directly on a fluid covered surface and applying pressure causes the (a) hydrophobic matrix to repel the fluid, (b) the bioadhesive particles to compress forming an adhesive layer, and (c) the bioadhesive particles to form temporary crosslinks followed by covalent crosslinks with the surface.
C09J 151/08 - Adhesives based on graft polymers in which the grafted component is obtained by reactions only involving carbon-to-carbon unsaturated bonds; Adhesives based on derivatives of such polymers grafted on to macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
The present disclosure relates to cytokine-induced memory-like NK cells expressing a chimeric antigen receptor polypeptide that binds to a neoepitope of mutant nucleophosmin (NPM1c) in complex with, or presented by, a class I major histocompatibility complex (MHC class I) protein, or cells expressing such compounds, and their use in methods for treating, or ameliorating one or more symptoms of, cancer.
The present disclosure relates to compounds (e.g., antibodies, antigen-binding fragments thereof, bispecific molecules, or chimeric antigen receptor polypeptides) that bind to a neoepitope of mutant nucleophosmin (NPM1c) in complex with, or presented by, a class I major histocompatibility complex (MHC class I) protein, or cells expressing such compounds, and their use in methods for treating, or ameliorating one or more symptoms of, cancer.
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Described is a cable comprising a plurality of high temperature superconductor (HTS) components, a plurality of electrically conductive segments extending along a length of the cable, each of the plurality of electrically conductive segments comprising one of the plurality of HTS components, and an electrically insulating material arranged between adjacent ones of the plurality of electrically conductive segments.
Disclosed herein are systems and methods for the injection of viscous fluids. For example, inventive systems and methods for injecting viscous fluids, such as concentrated drug formulations, via droplet lubrication are described.
The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the monomer, dopamine, polymerizes in vivo to form a polymer on a tissue. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.
The present disclosure provides compositions, methods, and kits that enable the in situ growth of polymers on or within a subject. In some aspects, the tissue-active monomers, including monomers comprising macromolecules, provide a broad set of material choices for synthetic tissue barriers. In additional aspects, the compositions, methods, and kits are useful for treating or preventing a disease or disorder.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (USA)
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (USA)
Inventor
Lai, Holden Wan Hong
Ahn, Jun Myun
Xia, Yan
Smith, Zachary P.
Benedetti, Francesco M.
Abstract
Disclosed herein are ladder polymers comprising fused aromatic and non-aromatic rings. Also disclosed are the manufacture and use of these ladder polymers, e.g., in separation membranes, such as membrane for gas separation.
Techniques described herein relate to systems and methods for obtaining a high temperature superconducting (HTS) cable assembly and filling the HTS cable assembly with a molten metal, such as solder.
TREATMENT OF ACID GASES USING MOLTEN ALKALI METAL BORATES AND ASSOCIATED METHODS OF SEPARATION, AND PROCESSES FOR REGENERATING SORBENTS AND ASSOCIATED SYSTEMS
The removal of acid gases (e.g., non-carbon dioxide acid gases) using non-COi acid gas sorbents that include salts in molten form, and related systems and methods, are generally described. Processes for regenerating sorbents at high temperatures, and associated systems, are also generally described.
B01D 53/14 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by absorption
B01D 53/78 - Liquid phase processes with gas-liquid contact
B01J 20/04 - Solid sorbent compositions or filter aid compositions; Sorbents for chromatography; Processes for preparing, regenerating or reactivating thereof comprising inorganic material comprising compounds of alkali metals, alkaline earth metals or magnesium
B01J 20/30 - Processes for preparing, regenerating or reactivating
45.
LASER-ASSISTED MATERIAL PHASE-CHANGE AND EXPULSION MICRO-MACHINING PROCESS
A laser micro-machining process called laser-assisted material phase-change and expulsion (LAMPE) micromachining that includes cutting features in a cutting surface of a piece of material using a pulsed laser with intensity, pulse width and pulse rate set to melt and eject liquid material without vaporizing said material, or, in the case of silicon, create an ejectible silicon oxide. Burrs are removed from the cutting surface by electro-polishing the cutting surface with a dilute acid solution using an electric potential higher than a normal electro-polishing electric potential. A multi-lamina assembly of laser-micro-machined laminates (MALL) may utilize MEMS. In the MALL process, first, the individual layers of a micro-electromechanical system (MEMS) are fabricated using the LAMPE micro-machining process. Next, the fabricated microstructure laminates are stack assembled and bonded to fabricate MEM systems. The MALL MEMS fabrication process enables greater material section and integration, greater design flexibility, low-cost manufacturing, rapid development, and integrated packaging.
B23K 26/00 - Working by laser beam, e.g. welding, cutting or boring
B23K 3/00 - Tools, devices, or special appurtenances for soldering, e.g. brazing, or unsoldering, not specially adapted for particular methods
B23K 26/38 - Removing material by boring or cutting
B81B 1/00 - Devices without movable or flexible elements, e.g. microcapillary devices
B81B 7/02 - Microstructural systems containing distinct electrical or optical devices of particular relevance for their function, e.g. microelectro-mechanical systems (MEMS)
Systems and methods for targeted gene modification, targeted insertion, perturbation of gene transcripts, and nucleic acid editing. Novel nucleic acid targeting systems comprise components of CRISPR systems and transposable elements.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
The use of biological fertilizer combined with microbes can be used instead of herbicides, pesticides and synthetic fertilizers. Silk and trehalose dry films can be used as seed coatings to localize and quantify delivery of plant microbes to mitigate plant stress and soil salinity. Similar microbes can be delivered using the same technology.
The present disclosure provides, in some aspects, macromonomers of Formula (I), and salts thereof; methods of preparing the macromonomers, and salts thereof; Brush prodrugs (polymers); methods of preparing the Brush prodrugs; compounds of Formula (II); conjugates of Formula (III), and salts thereof; pharmaceutical compositions comprising a Brush prodrug, or a conjugate or a salt thereof; kits comprising: a macromonomer or a salt thereof, a Brush prodrug, a compound, a conjugate or a salt thereof, or a pharmaceutical composition; methods of using the Brush prodrugs, or conjugates or salts thereof; and uses of the Brush prodrugs, and conjugates or salts thereof. These chemical entities may be useful in delivering pharmaceutical agents to a subject or cell.
C08G 61/08 - Macromolecular compounds containing only carbon atoms in the main chain of the macromolecule, e.g. polyxylylenes only aliphatic carbon atoms prepared by ring-opening of carbocyclic compounds of carbocyclic compounds containing one or more carbon-to-carbon double bonds in the ring
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
A61K 47/59 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
C08L 65/00 - Compositions of macromolecular compounds obtained by reactions forming a carbon-to-carbon link in the main chain; Compositions of derivatives of such polymers
Described herein are targeting moieties that can be capable of specifically targeting muscle cells and can include an n-mer motif. In some embodiments, the n-mer motif contains an RGD motif. Also described herein are vector systems, particles, polypeptides that can encode and/or contain one or more targeting moieties. Also described herein are methods of delivering a cargo to a cell, such as a muscle cell, using one or more of the targeting moieties described herein.
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
A61K 47/50 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
A61P 21/00 - Drugs for disorders of the muscular or neuromuscular system
C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
C07K 14/015 - Parvoviridae, e.g. feline panleukopenia virus, human parvovirus
C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
The present disclosure provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides Cas proteins and their use in modifying target sequences.
Centrifugal pump systems and related methods are disclosed herein that can shift a best efficiency point of a pump based on one or more operating conditions to operate more efficiently across and/or adjust to a broader range of conditions. Pumps provided for herein can include an adaptive volute in which a geometry of the volute can be adjusted to shift an operating efficiency of the pump. In some embodiments, a height or radial dimension of the adaptive volute can be adjusted based on one or more operating condition. A geometry of the adaptive volute can be adjusted during operation of the pump and/or while an impeller is disposed within the volute. In some embodiments, a first and second collar can be disposed within the adaptive volute. Rotation of the first component can move the second component axially, which can expand or contract an axial dimension of the adaptive volute.
Provided herein are compositions, systems, and methods for delivering cargo to a target cell. The compositions, systems, and methods comprise one or more polynucleotides encoding one or more endogenous retroviral elements for forming a delivery vesicle and one or more capture moieties for packaging a cargo within the delivery vesicle. The one or more endogenous retroviral elements for forming a delivery vesicle may comprise two or more of a retroviral gag protein, a retroviral envelope protein, a retroviral reverse transcriptase or a combination thereof. The retroviral gag protein alone, the retroviral envelope protein alone, or both the retroviral gag protein and retroviral envelope protein may be endogenous.
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
C12N 7/00 - Viruses, e.g. bacteriophages; Compositions thereof; Preparation or purification thereof
C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
53.
DEVICES AND METHODS FOR THE INTEGRATED FILTRATION, DRYING, AND MECHANICAL PROCESSING OF ACTIVE PHARMACEUTICAL INGREDIENTS
B01D 29/86 - Retarding cake deposition on the filter during the filtration period, e.g. using stirrers
B01D 29/03 - Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups ; Filtering elements therefor with flat filtering elements self-supporting
B01D 29/60 - Filters with filtering elements stationary during filtration, e.g. pressure or suction filters, not covered by groups ; Filtering elements therefor integrally combined with devices for controlling the filtration
The present disclosure is directed to systems, compositions, and methods for manufacturing objects with sharp edges having a high strength and hardness. To form the sharp edge, an object can be subjected to a compressive force that locally deforms the object to create the sharp edge. In some embodiments, deformation can occur by passing the material through a system of one or more opposed tapered rolls having one or more tapering angles for deforming the material. The tapered rolls can rotate and drive the material downstream to a next opposed pair of tapered rolls. The tapered rolls deform the material by changing the material microstructure, compressing the grains of the material in a predetermined location to create a more homogeneous microstructure. The local modification of the resulting microstructure increases the homogeneity as well as the hardness and strength of the material and prevents cracking and/or chipping of the material.
B24B 3/00 - Sharpening cutting edges, e.g. of tools; Accessories therefor, e.g. for holding the tools
C21D 7/00 - Modifying the physical properties of iron or steel by deformation
C22F 1/08 - Changing the physical structure of non-ferrous metals or alloys by heat treatment or by hot or cold working of copper or alloys based thereon
Described herein are methods of generating engineered viral capsid variants. Also described herein are engineered viral capsid variants, engineered viral particles and formulations and cells thereof. Also described herein are vector systems containing an engineered viral capsid polynucleotide and uses thereof.
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C07K 14/005 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
Methods, apparatuses, and systems related to electrochemical capture of Lewis acid gases from fluid mixtures are generally described. Certain embodiments are related to electrochemical methods involving selectively removing a first Lewis acid gas from a fluid mixture containing multiple types of Lewis acid gases (e.g., a first Lewis acid gas and a second Lewis acid gas). Certain embodiments are related to electrochemical systems comprising certain types of electro active species having certain redox states in which the species is capable of binding a first Lewis acid gas but for which binding with a second Lewis acid gas is thermodynamically and/or kinetically unfavorable. The methods, apparatuses, and systems described herein may be useful in carbon capture and pollution mitigation applications.
B01D 53/32 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
Methods, apparatuses, and systems related to the electrochemical separation of target gases from gas mixtures are provided. In some cases, a target gas such as carbon dioxide is captured and optionally released using an electrochemical cell (e.g., by bonding to an electroactive species in a reduced state). Some embodiments are particularly useful for selectively capturing the target gas while reacting with little to no oxygen gas that may be present in the gas mixture. Some such embodiments may be useful in applications involving separations from gas mixtures having relatively low concentrations of the target gas, such as direct air capture and ventilated air treatment.
B01D 53/32 - Separation of gases or vapours; Recovering vapours of volatile solvents from gases; Chemical or biological purification of waste gases, e.g. engine exhaust gases, smoke, fumes, flue gases or aerosols by electrical effects other than those provided for in group
Systems and methods are provided for semi-automated, portable, ultrasound guided cannulation. The systems and methods provide for image analysis to provide for segmentation of vessels of interest from image data. The image analysis provides for guidance for insertion of a cannulation system into a subject which may be accomplished by a non-expert based upon the guidance provided. The guidance may include an indicator or a mechanical guide to guide a user for inserting the vascular cannulation system into a subject to penetrate the vessel of interest.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
Articles and methods for delivering a therapeutic agent to a subject are described. These articles and methods may be useful, in some cases, for the delivery of therapeutic agents to the colon of a subject. In some embodiments, an article is configured to release a secretion inducing agent e.g., to stimulate the release of intestinal fluids. The article, in some embodiments, comprises a therapeutic agent such that the stimulated release of intestinal fluid increases the amount of therapeutic agent available for absorption by the colon. For example, in some embodiments, the articles and methods described herein advantageously promote increased absorption of therapeutic agents in subjects as compared to traditionally administered therapeutic agents without additional components such as a secretion inducing agent. In some embodiments, articles and methods described herein may increase the motility of the colon of a subject. The increase in contractions and movement of fluidic in the colon caused by increase motility may advantageously facilitate the dissolution or absorption of the therapeutic agent.
Wide-angle optical functionality is beneficial for imaging and image projection devices. Conventionally, wide-angle operation is attained by a complicated assembly of optical elements. Recent advances have led to meta-surface lenses or meta-lenses, which are ultra-thin planar lenses with nanoantennas that control the phase, amplitude, and/or polarization of light. Here, we present a meta-lens capable of diffraction-limited focusing and imaging over an unprecedented >170° angular field of view (FOV). The lens is integrated on a one-piece flat substrate and includes an aperture on one side and a single meta-surface on the other side. The meta-surface corrects third- order Seidel aberrations, including coma, astigmatism, and field curvature. The meta-lens has a planar focal plane, which enables considerably simplified system architectures for imaging and projection. The meta-lens design is generic and can be readily adapted to different meta-atom geometries and wavelength ranges to meet diverse application demands.
G02F 1/01 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics for the control of the intensity, phase, polarisation or colour
Synthetic hydrogels for organogenesis support organogenesis from mammalian cells, including human cells. The synthetic hydrogels typically include a network of crosslinked branched biodegradable polymers. A portion of the branches of the branched biodegradable polymers are linked to binders which are generally synthetic peptides for cell and extracellular matrix attachment. The hydrogels may include an inhibitor of apoptosis. The synthetic hydrogels with the synthetic binders typically do not interfere with cellular, proteomic, genetic, and/or transcriptome analyses of organoids formed in the hydrogel. The synthetic hydrogels may be subject to on-demand dissolution to provide intact organoids substantially free of hydrogel polymers. Also provided are methods of making the synthetic hydrogels and methods of using the synthetic hydrogels for organogenesis.
A device includes a grouping of N qubits, where N is equal to two or more, and a coherent light source configured to, given selected values for a set of parameters of at least a first and a second laser pulse, the parameters selected from a relative phase shift, a laser frequency, a laser intensity, and a pulse duration: apply at least the first and second laser pulses to all qubits within the grouping of N qubits, thereby coupling a non-interacting quantum state |1> to an interacting excited state |r), such that each qubit that begins in quantum state |1) returns to the state |1) upon completion of the at least first and second laser pulses, and such that qubits in the grouping are mutually blockaded.
Disclosed herein are compounds of Formula (I) or (II). The compounds include an agent (e.g., pharmaceutical agent, cosmetic agent, or nutraceutical agent) through a linker that includes a boronic ester moiety in the backbone of the linker. The compounds may be monomers. Also provided are polymers prepared by polymerizing the monomers. The polymers may be useful for delivering the agent to a subject, tissue, biological sample, or a cell. Also provided are methods of preparing the polymers, compositions and kits comprising the polymers, and methods of use (e.g., use in delivering the agent, treating a disease, preventing a disease, diagnosing a disease) involving the polymers or compositions. The structure of the boronic ester moiety may be fine tuned so that the properties related to delivery to a subject, biological sample, tissue, or cell may be fine tuned.
A system for optically modulating a plurality of optical channels includes a power delivery module adapted to convert a coherent light beam into a plurality of optical channels, at least one optical modulator, optically coupled to the power delivery module, the at least one optical modulator adapted to optically modulate each of the plurality of the optical channels, and a vacuum chamber having a trapping plane therein, the vacuum chamber adapted to generate an addressable array of trapped particles at the trapping plane, wherein each of the plurality of optical channels is optically coupled to at least one of the trapped particles of the addressable array.
G02F 1/00 - Devices or arrangements for the control of the intensity, colour, phase, polarisation or direction of light arriving from an independent light source, e.g. switching, gating or modulating; Non-linear optics
G06N 10/40 - Physical realisations or architectures of quantum processors or components for manipulating qubits, e.g. qubit coupling or qubit control
G02B 6/28 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals
G02B 6/293 - Optical coupling means having data bus means, i.e. plural waveguides interconnected and providing an inherently bidirectional system by mixing and splitting signals with wavelength selective means
Disclosed herein are compositions of retroviruses and methods of using the same for gene delivery, wherein the retroviruses comprise a viral envelope protein comprising at least one mutation that diminishes its native function, a non- viral membrane-bound protein comprising a membrane-bound domain and an extracellular targeting domain.
C12Q 1/6897 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
C12N 15/87 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
C12Q 1/70 - Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cells; Libraries contained in or displayed by vectors, e.g. plasmids; Libraries containing only microorganisms or vectors
Described herein are systems and methods for locating an object detected in a video. The system detects a bounding box at least partially around an object in a first frame at a first time in the video and a second frame in the video corresponding to a second time. The system determines whether there is no motion within the bounding box of the second frame. The system compares edge information, or color information, or intensity information associated with one or more pixels in the first frame, to edge information, or color information, or intensity information associated with one or more pixels within the bounding box. The system generates a score based on the comparison. The system further determines based on the score if the object is present in the second frame. The system also determines an estimated timeframe window of a first appearance of the object.
Circular RNA and transfer vehicles, along with related compositions and methods are described herein. In some embodiments, the inventive circular RNA comprises group I intron fragments, spacers, an IRES, duplex forming regions, and an expression sequence. In some embodiments, the expression sequence encodes a chimeric antigen receptor (CAR). In some embodiments, circular RNA of the invention has improved expression, functional stability, immunogenicity, ease of manufacturing, and/or half-life when compared to linear RNA. In some embodiments, inventive methods and constructs result in improved circularization efficiency, splicing efficiency, and/or purity when compared to existing RNA circularization approaches.
A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
C12N 15/115 - Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Dry adhesive materials, particularly in the form of a film or tape, for adhering one or more wet surfaces comprising: (i) one or more hydrophilic polymers; (ii) one or more amine coupling groups, and (iii) one or more cross linkers. The dry adhesive material, when placed in contact with the one or more wet surfaces, absorbs liquid from the one or more wet surfaces, swells to form temporary crosslinking with the wet surface, and forms covalent crosslinking with the one or more wet surfaces.
The present disclosure provides new prime editor guide RNAs for prime editing, constructs for prime editing, and methods for using same. In addition, the present disclosure provides compositions and methods for conducting prime editing of a target DNA molecule (e.g., a genome) that enables the incorporation of a nucleotide change and/or targeted mutagenesis (e.g., insertion or deletion). The nucleotide change can include a single-nucleotide change (e.g., any transition or any transversion), an insertion of one or more nucleotides, or a deletion of one or more nucleotides. More in particular, the disclosure provides fusion proteins comprising nucleic acid programmable DNA binding proteins (napDNAbp) and a polymerase (e.g., reverse transcriptase), which is guided to a specific DNA sequence by a prime editor RNA (PEgRNA). The prime editor guide RNA comprises an extension arm that provides a DNA synthesis template sequence which encodes a single strand DNA flap, which is homologous to an endogenous DNA sequence, but which contains the desired one or more nucleotide changes and which, following synthesis by the polymerase (e.g., reverse transcriptase), becomes incorporated into the target DNA molecule.
The present disclosure relates to synthetic oncolytic viruses comprising a lipid nanoparticle comprising one or more types of lipid and a self-amplifying replicon RNA comprising a sequence that encodes an immunomodulatory molecule.
A61K 35/768 - Oncolytic viruses not provided for in groups
A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
73.
LARGE-SCALE UNIFORM OPTICAL FOCUS ARRAY GENERATION WITH A PHASE SPATIAL LIGHT MODULATOR
A method of generating uniform large-scale optical focus arrays (LOT As) with a phase spatial light modulator (SLM) includes identifying and removing undesired phase rotation in the iterative Fourier transform algorithm (IFTA), thereby producing computer-generated holograms of highly uniform LOT As using a reduced number of iterations as compared to a weighted Gerchberg-Saxton algorithm. The method also enables a faster compensation of optical system-induced LOT A intensity inhomogeneity than the conventional IFTA.
The present invention provides biological samples of interest that have been iteratively expanded in a method referred to herein as iterative direct expansion microscopy (id-ExM). In the id-ExM method, biological samples of interest are permeated with a swellable material that results in the sample becoming embedded in the swellable material, and then the sample can be expanded isotropically in three dimensions. The process of iteratively expanding the samples can be applied to expand samples one or more additional times such that, for example, a 5-fold expanded sample can be expanded again to achieve high expansion factors, for example, 20x to 100x or more linear expansion.
This disclosure provides a method for imaging lymph nodes and lymphatic vessels without a contrast agent. The method includes providing, using an optical source, an infrared illumination to a region of a subject having at least one lymphatic component, detecting a reflected portion of the infrared illumination directly reflected from the region using a sensor positioned thereabout, and generating at least one image indicative of the at least one lymphatic component in the subject using the reflected portion of the infrared illumination.
The present disclosure provides, in some embodiments, in vitro blood brain barrier (iBBB) having functional properties of in vivo BBB as well as methods of identifying compounds capable of traversing the iBBB. Compounds capable of crossing the iBBB and therapeutic uses of such compounds are also described.
Reaction schemes involving acids and bases; reactors comprising spatially varying chemical composition gradients (e.g., spatially varying pH gradients), and associated systems and methods, are generally described.
The invention provides devices and methods for measuring how living cells function. The measurements can be made from tissue biopsy samples to measure functional properties of living cells from a solid tumor. After measuring a functional property of a cell, the cell remains alive and is available for other subsequent analyses. In certain aspects, the invention provides a method for measuring a cancer marker. The method includes obtaining a tissue sample comprising living cells, disaggregating the tissue sample and loading individual live cells into an input channel of a measurement instrument, and flowing the live cells through the measurement instrument to measure a functional property of the live cells.
The present description provides methods, assays and reagents useful for sequencing proteins. Sequencing proteins in a broad sense involves observing the plausible identity and order of amino acids, which is useful for sequencing single polypeptide molecules or multiple molecules of a single polypeptide. In one aspect, the methods are useful for sequencing multiple polypeptides. The methods and reagents described herein can be useful for high resolution interrogation of the proteome and enabling ultrasensitive diagnostics critical for early detection of diseases.
C07D 403/10 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing aromatic rings
G16B 30/00 - ICT specially adapted for sequence analysis involving nucleotides or amino acids
G16C 20/00 - Chemoinformatics, i.e. ICT specially adapted for the handling of physicochemical or structural data of chemical particles, elements, compounds or mixtures
C07D 403/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
C07D 403/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
The invention provides methods for evaluating disease, such as cancer, by way of performing multiple assays involving single-cell analysis on live cells isolated from a sample of a patient. The data obtained from the multiple assays is analyzed and linked to thereby provide a characterization of any given cell having undergone analysis, which, in turn, allows for evaluation of the sample either known to be, or suspected of being, cancerous. A report may be generated based on the data analysis, wherein the report provides information related to the cancer evaluation, including, but not limited to, whether the sample tested positive for cancer, a determination of a stage or progression of cancer, and a customized treatment plan tailored to an individual patient's cancer diagnosis.
Described herein are concepts, system and techniques which provide a means to construct robust high-field superconducting magnets using simple fabrication techniques and modular components that scale well toward commercialization. The resulting magnet assembly - which utilizes non-insulated, high temperature superconducting tapes (HTS) and provides for optimized coolant pathways - is inherently strong structurally, which enables maximum utilization of the high magnetic fields available with HTS technology. In addition, the concepts described herein provide for control of quench-induced current distributions within the tape stack and surrounding superstructure to safely dissipate quench energy, while at the same time obtaining acceptable magnet charge time. The net result is a structurally and thermally robust, high-field magnet assembly that is passively protected against quench fault conditions.
H01F 6/06 - Coils, e.g. winding, insulating, terminating or casing arrangements therefor
H01F 6/02 - Quenching; Protection arrangements during quenching
H01F 41/04 - Apparatus or processes specially adapted for manufacturing or assembling magnets, inductances or transformers; Apparatus or processes specially adapted for manufacturing materials characterised by their magnetic properties for manufacturing cores, coils or magnets for manufacturing coils
82.
CRISPR-ASSOCIATED TRANSPOSASE SYSTEMS AND METHODS OF USE THEREOF
The present application provides systems, methods and compositions used for targeted gene modification, targeted insertion, perturbation of gene transcripts, nucleic acid editing. Novel nucleic acid targeting systems comprise components of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) systems and transposable elements.
Immunotolerant engineered human tissue constructs are provided that are suitable for implantation into subjects. In some embodiments, the immunotolerance is controllable by an inducible system. Methods of making and using the immunotolerant engineered tissue constructs are provided.
A61F 2/00 - Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
A data processing system systems with parallel processors performing simulations by numerical solution of partial differential equations or similar numerical simulations. The data processing system extends the scaling limit of parallel solvers in those numerical simulations by overcoming the frequent network latencies encountered during a simulation. Fewer, yet larger batches of data are exchanged between computing nodes.
Actuating components and related methods are generally disclosed. Certain embodiments comprise an actuating component associated with a plurality of microneedles (e.g., for administering a therapeutic agent to a subject). In some embodiments, the actuating component may be administered to a subject such that the plurality of microneedles are deployed at a location internal to the subject (e.g., in the gastrointestinal tract). The actuating component may be contained within, in some embodiments, a capsule (e.g., for oral administration to a subject). In some embodiments, the actuating component has a pre-deployment configuration in which the plurality of microneedles have a first orientation and a deployed configuration in which the plurality of microneedles have a second orientation, different than the first orientation.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61M 5/00 - Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm rests
A61M 31/00 - Devices for introducing or retaining media, e.g. remedies, in cavities of the body
Aspects of the application relate to methods and systems for evaluating treatment response by measuring treatment-induced changes at the single cell level. The disclosure provides methods for isolating single cells that are primary cancer cells, including primary cancer cells from solid tumors, and detecting in minutes to hours from their removal from the body the response of such cells to anti-cancer agents such as radiation, small molecules, biologies, DNA damaging agents and the like.
Methods for generating primers and/or probes for use in analyzing a sample which may comprise a pathogen target sequence are provided, including identifying pan-viral sets of primers and/or probes.
RNA targeting proteins are utilized to provide a robust massively multiplexed CRISPR-based diagnostic by detection in droplets with attomolar sensitivity. Detection of both DNA and RNA with comparable levels of sensitivity at nanoliter volumes can differentiate targets from non-targets based on single base pair differences, with applications in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, and sensitive genotyping.
The present disclosure relates to improvements in the selection and formulation of PBAE polymers using a design of experiment approach, in which statistical methods are used to limit possible experimental conditions. The present disclosure relates to improved PBAE polymers and formulations.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
The present disclosure provides immunomodulatory fusion proteins comprising a collagen-binding domain operably linked to an immunomodulatory domain. The disclosure also features compositions and methods of using the same, for example, to treat cancer.
A neuromodulator may output stimuli that causes a user to fall asleep faster than the user would in the absence of the stimuli. Alternatively, the stimuli may modify a sleep state or behavior associated with a sleep state, or may cause or hinder a transition from a waking state to a sleep state or from a sleep state to another sleep state. The neuromodulator may take electroencephalography measurements. Based on these measurements, the neuromodulator may detect, in real time, instantaneous amplitude and instantaneous phase of an endogenous brain signal. The neuromodulator may output stimulation that is, or that causes sensations which are, phase-locked with the endogenous brain signal. In the course of calculating instantaneous phase and amplitude, the neuromodulator may perform an endpoint- corrected Hilbert transform. The stimuli may comprise auditory, visual, electrical, magnetic, vibrotactile or haptic stimuli.
A61M 21/02 - Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis for inducing sleep or relaxation, e.g. by direct nerve stimulation, hypnosis, analgesia
92.
SYSTEM AND METHOD FOR WIRELESS SENSING OF HEALTH MONITORING
An ultra-high frequency (UHF) wireless sensor includes an agent activated non-metal antenna formed of a conductive stimuli-responsive hydrogel material. A radio frequency identification (RFID) tag in electronic communication with the non-metal antenna includes a wireless data communication integrated circuit (IC). The non-metal antenna is configured to be inactive prior to an interaction with an activating agent and active upon the interaction with the activating agent.
A61F 13/42 - Absorbent pads, e.g. sanitary towels, swabs or tampons for external or internal application to the body; Supporting or fastening means therefor; Tampon applicators with wetness indicator or alarm
G06K 7/10 - Methods or arrangements for sensing record carriers by corpuscular radiation
G06K 19/07 - Record carriers with conductive marks, printed circuits or semiconductor circuit elements, e.g. credit or identity cards with integrated circuit chips
Provided herein are lipidoid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipidoid compounds, compositions, or formulations for treating and/or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein. The compounds are effective carriers for the delivery of an agent such as a polynucleotide (e.g., RNA) to a cell.
Described herein are compositions and methods for in vitro detection of nucleic acids. Nucleic acid sensors are activated for cell-free expression of an encoded reporter protein based on the presence of a target nucleic acid. The system is designed to function in low-cost cell extract without the need for instrumentation or stringent temperature control. These features are advantageous for point-of-use molecular diagnostics applications in consumer health, pet/animal health, food safety, and other areas where cost and portability are key factors.
The present invention generally relates to the generation of tunable coloration and/or interference from, for example, surfaces, emulsion droplets and particles. Embodiments described herein may be useful for generation of tunable electromagnetic radiation such as coloration (e.g., iridescence, structural color) and/or interference patterns from, for example, surfaces (e.g., comprising a plurality of microdomes and/or microwells), emulsion droplets and/or particles. In some embodiments, the surfaces, interfaces, droplets, and/or particles produce visible color (e.g., structural color) without the need for dyes.
The disclosure provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting Cas12b effector protein and at least one targeting nucleic acid component like a guide RNA or crRNA.
The present disclosure provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides mutated Cas13 proteins and their use in modifying target sequences as well as mutated Cas13 nucleic acid sequences and vectors encoding mutated Cas13 proteins and vector systems or CRISPR-Cas13 systems.
The embodiments disclosed herein utilized RNA targeting effectors to provide robust CRISPR-based nucleic acid amplification methods and systems. Embodiments disclosed herein can amplify both double-stranded and single-stranded nucleic acid targets. Moreover, the embodiments disclosed herein can be combined with various detection platforms, for example, CRISPR-SHERLOCK, to achieve detection and diagnostic with attomolar sensitivity. Such embodiments are useful in multiple scenarios in human health including, for example, viral detection, bacterial strain typing, sensitive genotyping, and detection of disease-associated cell free DNA.
Provided herein are methods and systems for detecting a target nucleic acid sequence. The method comprises contacting an oligonucleotide comprising the target nucleic acid sequence with a transposon complex; inserting one or more T7 RNA promoters into the oligonucleotide using the transposase; and (c) amplifying the target nucleic acid sequence. The transposon complex may comprise a transposase and a transposon sequence comprising one or more T7 RNA promoters. The target nucleic sequence may be amplified by generating RNA oligonucleotides comprising the target nucleic acid sequence via transcription from the inserted one or more T7 RNA promoters. The amplified target nucleic acid may be detected using a CRISPR Cas13-based detection system.
Provided herein are methods and systems for amplifying and/or detecting target double-stranded or single-stranded nucleic acids. The methods comprise combining a sample comprising the target nucleic acid with an amplification reaction mixture, amplifying the target nucleic acid, and further amplifying the target nucleic acid by repeated opening, unwinding, annealing and extension under isothermal conditions. The amplification reaction mixture may include an amplification CRISPR system, a helicase, a primer pair, and a polymerase. The amplification CRISPR system may comprise a first and second CRISPR/Cas complex, the first and second CRISPR/Cas complex may comprise a first CRISPR/Cas enzyme and a first guide molecule that guides the first CRISPR/Cas complex to a first strand of the target nucleic acid; the second CRISPR/Cas complex may comprise a second CRISPR/Cas enzyme and a second guide molecule that guides the second CRISPR/Cas complex to a second strand of the target nucleic acid.
patents
